

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Naxitamab
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Serb
Deal Size : $412.0 million
Deal Type : Acquisition
SERB Pharmaceuticals Agrees to Acquire Y-mAbs Therapeutics
Details : Through the acquisition, SERB will leverage Y-mAbs pipeline, including its lead commercial oncology asset, Danyelza (naxitamab). It is being indicated for neuroblastoma.
Product Name : Danyelza
Product Type : Antibody, Unconjugated
Upfront Cash : $412.0 million
August 05, 2025
Lead Product(s) : Naxitamab
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Serb
Deal Size : $412.0 million
Deal Type : Acquisition

Naxitamab + Irinotecan + Temozolomide Safety and Efficacy In Relapsed Neuroblastoma
Details : Naxitamab is a Antibody drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Neuroblastoma.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
June 18, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Naxitamab
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Nobelpharma
Deal Size : $33.0 million
Deal Type : Licensing Agreement
Y-mAbs And Nobelpharma Sign DANYELZA® Deal for Japanese Market
Details : The agreement aims for the development and commercialization in Japan of Danyelza (naxitamab) for high-risk neuroblastoma and, upon agreement by the parties, potentially relapsed osteosarcoma.
Product Name : Danyelza
Product Type : Antibody, Unconjugated
Upfront Cash : $2.0 million
November 04, 2024
Lead Product(s) : Naxitamab
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Nobelpharma
Deal Size : $33.0 million
Deal Type : Licensing Agreement

Details : Naxitamab is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Neuroblastoma.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
September 21, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Naxitamab,GM-CSF
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Y-mAbs DANYELZA (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma Approved in Brazil
Details : Danyelza® (naxitamab-gqgk) binds to the glycolipid GD2, indicated in combination with GMCSF, for the treatment of relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response to prior...
Product Name : Danyelza
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
May 23, 2023
Lead Product(s) : Naxitamab,GM-CSF
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Naxitamab,GM-CSF
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Danyelza® (naxitamab-gqgk) binds to the glycolipid GD2, indicated in combination with GMCSF, for the treatment of relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response to prior...
Product Name : Danyelza
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
February 02, 2023
Lead Product(s) : Naxitamab,GM-CSF
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Naxitamab,GM-CSF
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : WEP Clinical
Deal Size : Undisclosed
Deal Type : Partnership
Y-mAbs Announces Partnership Regarding Early Access Program for DANYELZA (naxitamab-gqgk) in Europe
Details : Danyelza (naxitamab-gqgk) is a humanized, monoclonal antibody that binds to the glycolipid GD2. GD2 is a disialoganglioside that is overexpressed on neuroblastoma cells and other cells of neuroectodermal origin, including the central nervous system and p...
Product Name : Danyelza
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
December 21, 2022
Lead Product(s) : Naxitamab,GM-CSF
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : WEP Clinical
Deal Size : Undisclosed
Deal Type : Partnership

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Naxitamab,GM-CSF
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma Approved in China
Details : DANYELZA (naxitamab) is a humanized, monoclonal antibody that targets the ganglioside GD2, which is highly expressed in various neuroectoderm-derived tumors and sarcomas. DANYELZA is administered three times in a week in an outpatient setting and is repe...
Product Name : Danyelza
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
December 08, 2022
Lead Product(s) : Naxitamab,GM-CSF
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Naxitamab,GM-CSF
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Memorial Sloan Kettering Cancer Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Y-mAbs Announces Regulatory Filing for DANYELZA® (naxitamab-gqgk) in Brazil
Details : DANYELZA (naxitamab-gqgk) is indicated, in combination with granulocyte-macrophage colony-stimulating factor for treatment of pediatric patients 1 year of age and older and adult patients.
Product Name : Danyelza
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
September 26, 2022
Lead Product(s) : Naxitamab,GM-CSF
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Memorial Sloan Kettering Cancer Center
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Naxitamab,GM-CSF,Temozolomide
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DANYELZA® (naxitamab-gqgk), which targets tumors that express GD2, and one product candidate at the registration-stage, OMBLASTYS® (omburtamab), which targets tumors that express B7-H3.
Product Name : Danyelza
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
May 26, 2022
Lead Product(s) : Naxitamab,GM-CSF,Temozolomide
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
